The Influence Of The Infusion Of Ephedrine And Phenylephrine On The Hemodynamic Stability After Subarachnoid Anesthesia In Senior Adults - A Controlled Randomized Trial

CURRENT STATUS: ACCEPTED

Miodrag Vojislav Žunić miodrag.zunic@doctor.com
Univerzitetni Klinicni Center Maribor; Medical faculty University of Maribor, Slovenia
Corresponding Author
ORCiD: 0000-0003-0538-7497

Nevenka Krčevski Škvarč
University clinical centre Maribor

Mirt Kamenik
University Clinical Centre Maribor

DOI: 10.21203/rs.2.10804/v2

SUBJECT AREAS
Anesthesiology & Pain Medicine

KEYWORDS
spinal anesthesia, hemodynamic stability, phenylephrine, ephedrine
Abstract

ABSTRACT Study objective: We studied the influence of ephedrine or phenylephrine infusion given immediately after spinal anesthesia (SA) on hemodynamics in elderly orthopedic patients. Design: A prospective, randomized, double-blind, placebo-controlled study. Intervention: After subarachnoid injection of 15 mg of levobupivacaine the participants received either an infusion of ephedrine 20 mg (E group), phenylephrine 250 mcg (P group) or saline (C group) within 30 minutes. For 15 minutes before and and 30 minutes after SA we measured blood pressure, cardiac index (CI) and heart rate (HR).

Results 70 patients were included in the final analysis. At the end of measurements mean arterial pressure decreased significantly after SA in comparison to baseline in the C group but was maintained in the P and the E group, with no significant differences between the groups. CI decreased after SA in the C group was maintained in the P group and increased significantly in the E group, with significant differences between the C and the E group (p=0.049) and between the P and the E (p=0.01) group at the end of measurements. HR decreased significantly after SA in the C and the P group and was maintained in the E group, with significant differences between the P and the E group (p=0.033) at the end of measurements. Conclusions Hemodynamic changes after SA in elderly orthopedic patients can be prevented by an immediate infusion of phenylephrine or ephedrine. In addition to maintaining blood pressure the ephedrine infusion also maintains HR and increases CI after spinal anaesthesia. Key words: spinal anesthesia, hemodynamic stability, phenylephrine, ephedrine Trial registration: ISRCTN registry ISRCTN44377602. Registered on 15 June 2017.

Background

Many European countries', England's, Australia's and Canada's national arthroplasty
registers have showed an increasing of the prevalence of the hip and knee arthroplasty over the last decades [1, 2, 3, 4]. The number of such procedures in the future seems to be even higher [3]. Many of those are elderly patients, ASA 1 to 4 [1].

A commonly used technique for elderly patients undergoing orthopedic surgery is spinal anesthesia (SA) [5, 6]. Hypotension is a side effect often associated with SA [7]. The incidence of SA-induced hypotension (SAIH) in the elderly is due to a decrease of the systemic vascular resistance (SVR) and cardiac output (CO) [5] estimated almost 80% [8]. The high incidence of comorbid conditions in the elderly leads to high risk for hypoperfusion caused by hypotension, [5, 9, 10], which main risk factor is hypovolemia [11, 12]. The administration of crystalloids can quickly lead to volume overload and signs of congestive heart failure in the elderly and is often not effective in maintaining blood pressure [5]. Therefore, ephedrine and phenylephrine are the vasopressors of choice for the prevention of SAIH in the elderly [8].

The objective of our study was to evaluate the effectiveness of prophylactic intravenous (IV) ephedrine or phenylephrine infusion on the prevention of hypotension and a decrease in CO following SA in patients older than 60 years undergoing elective orthopedic surgery.

Methods

Our prospective, randomized, double-blind, placebo-controlled study was approved by the National Medical Ethics Committee at the Ministry of Health, Republic of Slovenia (protocol number 0120-8/2017-3, KME 21/01/17. The trial was retrospectively registered at ISRCTN with the submission number ISRCTN44377602. We studied 84 patients older than 60 years, scheduled for orthopedic hip or knee replacement surgery under SA. Written informed consent was obtained from each patient. Participant exclusion criteria were any contraindications to SA (absolute: patients’ refusal, infection at the site of injection,
uncorrected hypovolemia, allergy, increased intracranial pressure or relative: coagulopathy, sepsis, fixed CO states, indeterminate neurological disease) or administration of vasoconstrictors (allergy or hypersensitivity to vasoconstrictors, unstable angina, recent coronary artery bypass surgery, recent myocardial infarction refractory arrhythmias, untreated or uncontrolled severe hypertension, untreated or uncontrolled heart failure, uncontrolled hypothyroidism, sulfite sensitivity, uncontrolled diabetes, pheochromocytoma, use of cocaine, monoamine oxidase inhibitors, phenothiazine compounds or tricyclic antidepressants).

Patients were fasted the night before the surgery. Antihypertensive medications were discontinued the day before the surgery, except the $\beta$-blockers. Midazolam 7.5 mg was given for premedication one hour before the surgery. After the patient arrival in the operating room, an IV line was inserted and the patient was placed in the lateral decubitus position. Using the paramedian approach with a 25-gauge Sprotte needle (PAJUNK, GmbH, Geisingen, Germany) we performed lumbar puncture at the L2–L3 interspace. With the needle aperture oriented in the cephalad direction, 3mL of 0.5% levobupivacaine (Chirocaine 0.5% plain; AbbVie, Campoverde, Italia) were injected within 15 seconds. All the patients received an infusion of 1000 mL lactated Ringer solution within 45 minutes from the beginning of the measurement (500 ml before and 500 ml after SA). With respect to the infusion of treatment medication, the patients were randomly assigned to one of the three groups using sealed envelope randomization. The C group (control group) received an infusion of 30 ml 0.9% NaCl 30 minutes after SA. The P group (phenylephrine group) received a continuous infusion of 30 ml of 0.9% NaCl with 250 mcg of phenylephrine 30 minutes after SA. The E group (ephedrine group) received a continuous infusion 30 ml of 0.9% NaCl with 20 mg of ephedrine 30 minutes after SA. The infusion of the treatment medication in all the groups was started immediately after SA (Figure 1).
We measured non-invasive blood pressure, non-invasive CO using thoracic electrical bioimpedance (TEB) method, heart rate and pulse oximetry (SpO₂) using the AESCULON, OSYPCA MEDICAL, 2011, monitor.

We started hemodynamic measurements 5 minutes after placing the patient in the lateral decubitus position and we recorded it for 45 minutes (for 15 minutes before and 30 minutes after the injection of the local anesthetic solution into the subarachnoid space). Data on blood pressure were recorded and stored on the hard drive at 5-minute intervals and other hemodynamic data at 1-minute intervals.

The protocol for rescue treatment in the event of hemodynamic instability included:

1. Severe hypotension (decrease of systolic blood pressure for more than 30% from baseline, or systolic blood pressure less than 80 mmHg): additional ephedrine boluses of 5 mg repeated in 3 minutes with additional infusion of Ringer solution or additional phenylephrine boluses of 50 mcg repeated in 3 minutes with additional infusion of Ringer solution.

2. Bradycardia (≤50 beats per minute): bolus of atropine 0.5 mg, repeated in 1 minute until heart rate frequency is more than 50 beats per minute or overall amount of 2 mg atropine is reached.

3. Hypertension (increase of systolic blood pressure for more than 30% from baseline): discontinuation of the ongoing infusion.

Hypotensive, hypertensive or bradycardic patients were defined as patients who developed at least one episode of hypertension, hypotension or bradycardia throughout the case and were treated according to the protocol.

Data were analyzed with the SPSS 25.0.0. software. Demographic data and baseline values were compared with one-way analysis of variance and χ², where appropriate. The
hemodynamic data before, 10, 20 and 30 minutes after SA were compared with ANOVA with Bonferroni correction for post hoc comparisons and the Student’s t-test for paired samples, where appropriate. In addition, the analysis of variance for repeated measurements with Bonferroni correction was performed to compare the change in hemodynamic measurements between the three treatment groups and the change over time. P<0.05 was considered statistically significant.

Sample size calculation to detect a 20% difference in CI (0.5 L/min/m$^2$) between treatment groups, assuming a mean CI of 2.5 L/min/m$^2$ and SD of 0.5 L/min/m$^2$ with a probability level of 0.05 and a power of 0.85, yielded a sample size of 69 patients. The same number of patients would detect a 10mmHg difference between the groups in MAP (assuming SD of 10 mmHg) with a probability level of 0.05 and a power of 0.85. Expecting dropouts due to various reasons, including side effects, we randomized 90 patients. We used the G Power 3.1.9.2. software for these calculations.

Results

We randomized 90 patients. Four patients were excluded because they declined to participate and two patients were excluded for not meeting the inclusion criteria (Figure 2). Patients with side effects requiring a rescue protocol were excluded from final analysis and were analyzed separately. Seven patients from the C group were excluded because of hemodynamic instability (5 patients got severe hypotension, one had bradycardia and one had hypotension with bradycardia). Two patients were excluded from the P group because of hypotension with bradycardia and two had hypotension episode alone. Two patients were excluded from the E group because of hypotension, one patient because of bradycardia and hypotension. Therefore, 70 patients were included in the final analysis: Twenty-five patients in the E group, twenty-four in the P group and twenty-one patients in
the C group.
There were no significant differences between the groups with respect to the demographic data and baseline hemodynamics (Table 1).

The change in hemodynamic data after spinal block in the three treatment groups is shown in Figure 3. The decrease in MAP after spinal block was most prominent in the C group and was statistically significant 10, 20 and 30 minutes after the block. In the P group a transient statistically significant decrease in MAP was measured 10 (p=0.002) and 20 (p=0.02) minutes after the block, but by the end of measurements MAP returned to about baseline values. MAP was maintained after SA in the E group. At the end of measurements, the decrease in MAP was significantly higher in the C group compared to the E (p=0.004) and P group (p=0.043), but there were no differences between the P and E group (Figure 3).

The percentage in CI after SA decreased non-significantly in the C and P group (Figure 3). In the E group of patients, the percentage in CI significantly increased after SA. At the end of measurements, the percentage in CI was significantly increased in the E group in comparison to the C (p<0.001) and P group (p=0.002), with no differences between the C and P group. HR decreased significantly after SA in the C and P group but not in the E group (Figure 3). At the end of measurements, the decrease of HR after SA was significantly higher in the C (p=0.017) and P group (p=0.013) in comparison to the E group, with no significant differences between the C and P group (Figure 3). The percentage in SVI did not change after SA in the C group, transiently increased (10 minutes after the block) in the P group (p= 0.036) and increased significantly in the E group (p=0.049) [Figure 3]. 20 minutes after SA the increase in SVI was significantly higher in the E group in comparison with the C (p=0.02) and P group (p=0.48) [Figure 3]. Fourteen patients was with side effects (Table 2). There were no significant differences
between groups. The incidence of bradycardic and hypotensive events (n=14) was not statistically different between the treatment groups (p=0.33). Although the number of the bradycardic (n=3) and the hypotensive (n=6) patients was higher in the group C, the differences between the groups did not reach statistical significance (p=0.86 and p=0.53). There were no significant differences between the groups with respect to the number of patients receiving ephedrine (p=0.58) or phenylephrine (p=0.54) as the rescue drug.

Discussion

We studied the influence of prophylactic treatment with two different vasopressors (ephedrine and phenylephrine) on the prevention of hypotension after SA and the changes on hemodynamics in the elderly patients. The topic is undoubtedly very important and to our knowledge, our study is the first, which documented the efficacy of a prophylactic ephedrine infusion after SA in elderly.

All the patients in our study were receiving a continuous infusion of Ringer’s solution during the time of measurements. The study showed that the additional infusion of ephedrine maintained the MAP after SA (E group), the additional infusion of phenylephrine caused a temporary slight decrease in MAP (P group), but MAP returned to baseline at the end of measurements. In patients not receiving vasopressors (C group), MAP decreased after SA by about 14%. CI was maintained after SA in the C and P group and increased in the E group by about 14%. HR decreased after SA in the C and P group and was maintained in the E group.

Nakasuji et al. showed a decrease in SVR, not CO, is the main mechanism of hypotension seen during SA in elderly patients [13]. Marhofer and co-workers [14] also showed that SAIH in elderly ASA 3 patients was caused by a decrease in systemic vascular resistance index, without change in cardiac index. Kamenik and Eržen [15] showed that CO decreases after SA in the group of middle-aged patients not receiving crystalloids as well as in the
group of patients who received crystalloids before SA, while CO increases in the group of patients receiving lactated Ringer's solution at the time of spinal block. Later on, Zorko and Kamenik [16] have shown that the infusion of 1000 mL of lactated Ringer after spinal block prevented the decrease of CO after SA, CO was actually increasing while the infusion was running. In our study, we used a slightly modified hydration strategy. We infused 1000 ml of Ringers solution continuously during the period of measurements (15 minutes before and 30 minutes after SA). Our results show that with this regimen we were able to maintain CI after SA at about baseline values in the C group of patients. However, in this group of patients we were not able to maintain the MAP. The MAP decreased due to a decrease in vascular resistance. In addition, HR also decreased after SA in the C group of patients. With an additional infusion of phenylephrine, which is a pure a vasoconstrictor, we were able to prevent the decrease in vascular resistance. This resulted in only slight transient decrease in MAP. However, the infusion of phenylephrine did not prevent the decrease in HR after SA. In the study of Stewart et al., the authors found a dose-dependent reduction in both maternal HR and CO, measured with suprasternal Doppler, when comparing three different infusion regimens of phenylephrine. The highest infusion rate reduced both CO and HR by >20% [17]. In our study in the P group of patients, HR also decreased, but CI was maintained probably because of the continuous infusion of Ringers solution. In the E group of patients with the infusion of ephedrine, we were able to maintain the MAP and the HR and the CI increased due to the additional increase in SVI caused by the inotropic action of ephedrine.

The incidence of patients with side effects was higher in the C group of patients (n=7) in comparison with the P group (n=4 and the E group (n=3). Although the differences were not statistically significant (due to a low sample size), a nearly double incidence of side effects shows that hemodynamic side effects after SA (bradycardia and hypotension) can
be prevented with a prophylactic infusion of vasopressors. Since the main interest in our study was hemodynamics of vasopressors, we decided to exclude the patients with side effects requiring rescue drugs in the final data presentation.

The best vasopressor to be used after SA is still not known. The current opinion in obstetrics favors the use of phenylephrine over ephedrine as alpha agonist of choice for treating hypotension associated with SA due to its beneficial effect on fetal acid-base balance and umbilical pH [18,19]. Mon and coworkers have shown that ephedrine infusion was associated with good systolic blood pressure control and no reduction in both the maternal CO and HR, than those in phenylephrine group [20]. On the other hand, Larson et al. [21] reviewed that many researchers suggest phenylephrine may adversely affect cerebral oxygen saturation and perfusion. The authors stated that the use of phenylephrine to treat SAIH is a ubiquitous practice among anesthesia providers, despite the fact that it has never been shown to improve outcomes. Another approach could be the combined use of the vasopressors and different timings, but according to Das et al. [22], in obstetric patients such combination of half the usual dose of ephedrine and phenylephrine had no supreme outcome.

Regardless of prehydration, a high incidence of hypotension (the overall incidence of SAIH was 49%, ranging from 39% in the colloid group to 62% in the crystalloid group) follows SA in normovolemic elderly patients undergoing elective procedures [23]. Our study shows the importance of prophylactic infusion treatment with vasopressors in this group of patients, but a definite and widely available method of predicting pre-operative hypotension is not identified yet. Berlac and Rasmunssen suggested that NIRS could provide an early warning of hypotension [24]. On the other hand, Hanss et al. reported that women who developed more severe hypotension after SA had greater changes in heart rate variability [25].
In our study, CO was measured with TEB, noninvasively. Most researchers have accepted the TEB method for monitoring the trends of change in CO, but the absolute value of CO measured with TEB is controversial [26-28]. As a non-invasive method in spontaneously breathing patients during SA, it has an advantage over invasive methods, which are ethically rarely justified [29]. In our study, the TEB method was used also as a trend monitor to follow the changes in hemodynamic parameters after SA.

Conclusions

In conclusion, our study shows that we can decrease the incidence of side effects and the decrease in MAP after SA with the combination of the Ringers solution infusion with the infusion of ephedrine or an infusion of phenylephrine. An ephedrine infusion also prevents a decrease in HR and increases cardiac output, while an infusion of phenylephrine maintains CO, but is accompanied by a decrease in HR. Since flow is better maintained, we recommend the infusion of ephedrine in elderly receiving SA. Further studies are necessary to evaluate the duration of the effects of the infusion of ephedrine and the optimal dose to improve hemodynamic stability after SA in the elderly.

Abbreviations

ANOVA-analysis of variance
ASA-the American Society of Anesthesiologists
C group -control group
CI-cardiac index
CO-cardiac output
E group-ephedrine group
IV-intravenous
HR-hearth rate
MAP-mean arterial pressure
NIRS-near-infrared spectroscopy
P group -phenylephrine group
pH-power of hydrogen
SA-spinal anesthesia
SAIH- spinal anesthesia induced hypotension
SAP-systolic arterial pressure
SD-standard deviation
SPSS- statistical package for the social sciences
SV-stroke volume
SVI-stroke volume index
SVR-systemic vascular resistance
TEB-thoracic electrical bioimpedancy

Declarations

**Ethics approval and consent to participate**

**Ethics approval:** This study was approved by the National Medical Ethics Committee at Ministry of Health, Republic of Slovenia, 5 Štefanova Street, 1000 Ljubljana, Slovenia, Europe,
under reference number: 0120-8/2017-3, KME 21/01/17-bis.

**Consent to participate:** Written informed consent was obtained from all study participants.

**Consent for publication:** Not applicable.

**Availability of data and materials:** The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Competing interests:** The authors declare that they have no conflict of interest.
Funding: The study was supported by the University Clinical Centre Maribor and was not supported by any other grant money or other direct financial aid.

Authors’ contributions: MZ was the primary researcher. He has contributed to study design, patient recruitment, data collection, interpretation of the results and wrote the original draft of the manuscript. NKS has contributed to study design, interpretation of the results and revised the manuscript for important intellectual content. MK has contributed to study design, analyzed the data, interpreted the results and revised the manuscript for important intellectual content. All authors read and approved the final manuscript.

Acknowledgments: Not applicable

References

1. Lübbeke, Silman AJ, Barea C., Prieto-Alhambra, Carr AJ. Mapping existing hip and knee replacement registries in Europe. Health Policy 2018; 122:548-57.
2. Kremers HM, Larson DR, Crowson MS, Kremers WK, Washington RE, Steiner CA, Jiranek WA, Berry DJ. Prevalence of total hip and knee replacement in the United States. J Bone Joint Surg Am 2015; 97:1386-97.
3. Kurz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am 2007; 89:780-5.
4. Singh JA. Epidemiology of knee and hip arthroplasty: a systematic review. The Open Orthopaedics Journal, 2011;5:80-5.
5. Ferré F, Marty P, Bruneteau L, Merlet V, Bataille B, Ferrier A, Gris C, Kurrek, Fourcade O, Minville V, Sommet A. Prophylactic phenylephrine infusion during spinal anesthesia. Journal of Clinical Anesthesia 2016; 35: 99-106.
6. Urwin SC, Parker MJ, Griffiths R. General versus regional anesthesia for hip fracture surgery: a meta-analysis of randomized trials. Br J Anesth 2000; 84: 450-5.
7. Tarkkila PJ, Kaukinen S. Complications during spinal anesthesia: a prospective study. Reg Anesth 1991; 16: 101-6.

8. Minville V, Fourcade O, Grousset D, Chassery C, Nguyen L, Asehnoune K, et al. Spinal anesthesia using single injection small-dose bupivacaine versus continuous catheter injection techniques for surgical repair of hip fracture in elderly patients. Anesth Analg 2006; 102: 1559-63.

9. Ferré F, Minville V. Preoperative management to reduce morbidity and mortality of hip fracture. Ann Fr Anesth Reanim 2011; 30:45-8.

10. Rivera R, Antognini JF. Perioperative drug therapy in elderly patients. Anesthesiology 2009; 110:1176-81.

11. Tarkkila P, Isola J. A regression model for identifying patients at high risk of hypotension, bradycardia and nausea during spinal anesthesia. Acta Anaesthesiol Scand 1992;36 (6):554–558.

12. Hartmann B, Junger A, Klasen J, et al. The incidence and risk factors for hypotension after spinal anesthesia induction: an analysis with automated data collection. Anesth Analg 2002;94 (6):1521–1529; table of contents.

13. Nakasuji M, Suh SH, Nomura M, Nakamura M, Imanaka N, Tanaka M, Nakasuji K. Hypotension from spinal anesthesia in patients aged greater than 80 years is due to a decrease in systemic vascular resistance. J Clin Anesth 2012; 24(3): 201-6.

14. Marhofer P, Faryniak B, Oismueller C, Koinig H, Kapral S, Mayer N. Cardiovascular effects of 6% hetastarch and lactated Ringer’s solution during spinal anesthesia. Reg Anesth Pain Med 1999; 24: 399-404.

15. Kamenik M, Paver-Eržen V. The effects of Lactated Ringer’s solution infusion on cardiac output changes after spinal anesthesia. Anesth Analg 2001; 92: 710-4.

16. Zorko N, Kamenik M, Starc V. The effect of Trandelenburg position, lactated Ringer’s
solution and 6% hydroxyethyl starch solution on cardiac output after spinal anesthesia. Anesth Analg 2009; 108(2): 655-9.

17. Stewart A, Fernando R, McDonald S, Hignett R, Jones T, Columb M. The dose-dependent effects of phenylephrine for elective cesarean delivery under spinal anesthesia. Anesthesia and Analgesia 2010; 111: 1230-7.

18. Veeser M, Hofmann T, Roth R, Klöhr S, Rossaint R, Heesen M. Vasopressors for the management of hypotension after spinal anesthesia for elective caesarean section. Systematic review and cumulative meta-analysis. Acta Anaesthesiol Scand 2012; 56: 810-6.

19. Kinsella SM, Carvalho B, Dyer RA, Fernando R, McDonnell N, Mercier FJ, Palanisamy A, et al. International consensus statement on the management of hypotension with vasopressors during caesarean section under spinal anaesthesia. Anaesthesia 2018; 73: 71-92.

20. Mon W, Stewart A, Fernando R, Ashpole K, El-Wahab N, MacDonald S, Tamilselvan P, Columb M, Liu YM. Cardiac output changes with phenylephrine and ephedrine infusions during spinal anesthesia for cesarean section: A randomized, double-blind trial. J Clin Anesth. 2017 Feb; 37:43-48.

21. Larson SL, Anderson LR, Thomson JS. The effect of phenylephrine on cerebral perfusion when used to treat anesthesia-induced hypotension: a systematic review protocol. JBI Database System Rev Implement Rep 2018; 16(6): 1346-53.

22. Das S, Mukhopadhyay S., Mandal M, Mandal S, Basu RS. A comparative study of infusions of phenylephrine, ephedrine and phenylephrine plus ephedrine on maternal haemodynamics in elective caesarean section. Indian J Anaesth 2011; 55(6): 578-83.

23. Buggy D, Higgins P, Moran C, O’Brien D, O’Donovan F, McCarroll M. Prevention of spinal anesthesia-induced hypotension in the elderly: Comparison between
preanesthetic administration of crystalloids, colloids, and no prehydration. Anesth Analg 1997; 84: 106-10.

24. Berlac PA, Rasmussen YH. Per-operative cerebral near-infrared spectroscopy (NIRS) predicts maternal hypotension during elective caesarean delivery in spinal anaesthesia. International Journal of Obstetric Anesthesia 2005; 14: 26-31.

25. Hanss R, Bein B, Ledowski T, et al. Heart rate variability predicts severe hypotension after spinal anesthesia for elective cesarean delivery. Anesthesiology 2005; 102: 1086-93.

26. Malik V., Subramanian A., Chauhan S. and Hote M. Correlation of electric cardiometry and continuous thermodilution cardiac output monitoring systems. World Journal of Cardiovascular Surgery 2014; 4:101-8.

27. Butterworth JF, Piccione W, Berrizbeitia LD, Dance G, Shemin RJ, Cohn LH. Augmentation of venous return by adrenergic agonists during spinal anesthesia. Anesth Analg 1986; 65: 612-6.

28. Rooke GA, Freund PR, Jacobson AF. Hemodynamic response and change in organ blood volume during spinal anesthesia in elderly men with cardiac disease. Anesth Analg 1997; 85:99-105.

29. Ngan Kee WD, Khaw KS, Ng FF, Lee BB. Prophylactic phenylephrine infusion for preventing hypotension during spinal anesthesia for cesarean delivery. Anesth Analg 2004; 98: 815-21.

Tables

Table 1. Demographic data and baseline hemodynamic measurements in the three groups of patients
| GROUP | C | P | E |
|-------|---|---|---|
| Number of patients | 21 | 24 | 25 |
| Gender (male/female) | 5/16 | 8/16 | 5/20 |
| Age (years) | 67.9 (± 5.5) | 71.1 (± 7.7) | 68.4 (± 6.6) |
| Height (cm) | 166.2 (± 8.2) | 158.8 (± 34.6) | 164.6 (± 11.5) |
| Weight (kg) | 79.7 (± 13.5) | 86.0 (± 13.6) | 82.1 (± 14.2) |
| ASA I/ ASA II/ ASA III | 3/12/6 | 2/15/7 | 1/17/7 |
| BMI | 28.8 (± 4.5) | 31.3 (± 5.0) | 30.2 (± 3.9) |
| BSA | 1.9 (± 0.2) | 1.9 (± 0.2) | 1.9 (± 0.2) |
| SBP (mmHg) \(^a\) | 134 (± 22) | 128 (± 17) | 125 (± 15) |
| MAP (mmHg) \(^a\) | 90 (± 12) | 85 (± 12) | 84 (± 9) |
| HR (beats/min) \(^a\) | 75.4 (± 11.0) | 73.5 (± 11.6) | 74.7 (± 11.7) |
| CI(BSA) (l/min/m\(^2\)) \(^a\) | 2.5 (± 0.7) | 2.2 (± 0.5) | 2.5 (± 0.6) |
| SVR (dyns cm\(^{-5}\)) \(^a\) | 886 (± 292) | 863 (± 233) | 850 (± 320) |
| SI(BSA) (ml/m\(^2\)) \(^a\) | 33.1 (± 5.8) | 30.3 (± 6.0) | 32.8 (± 6.7) |

SBP = systolic blood pressure, MAP = mean arterial pressure, CO = cardiac output,
SVR = systemic vascular resistance
Values are mean (± SD)
\(^a\) Baseline values defined as last registered values before SA

Table 2. Number of patients developing side effects, time to onset of side effect and rescue medication in each treatment group. Seven patients developed hypotension and bradycardia.
| GROUP | | | |
|---|---|---|---|
| | C | P | E |
| **BRADYCARDIA** | | | |
| Number of patients | 3/28 | 2/28 | 2/28 |
| Time to event (min) | 26.7 ± 8.1 | 23.5 ± 2.1 | 27.5 ± 17.1 |
| Dose of atropine (mg) | 0.7 ± 0.3 | 0.5 ± 0 | 0.5 ± 0 |
| **HYPOTENSION** | | | |
| Number of patients | 6/28 | 4/28 | 3/28 |
| Time to event (min) | 25.8 ± 6.7 | 27.3 ± 5.6 | 27 ± 7.1 |
| Ephedrine | | | |
| Number of patients | 3/28 | 1/28 | 2/28 |
| Dose of ephedrine a (mg) | 11.7 (10-15) | 10 | 10 (10) |
| Phenylephrine | | | |
| Number of patients | 3/28 | 3/28 | 1/28 |
| Dose of phenylephrine a (mg) | 100 (100) | 167 (100-300) | 100 (100) |

**Figures**

![Study protocol](image)

**Figure 1**

Study protocol: Fluid flow-chart.
Assessed for eligibility (n=90)

Excluded (n=6)
Not meeting inclusion criteria (n=2)
Declined to participate (n=4)

28 allocated to receive phenylephrine
- 28 received phenylephrine

24 included in analysis
Discontinued intervention (n=4)

28 allocated to receive saline
- 28 received saline

21 included in analysis
Discontinued intervention (n=7)

28 allocated to receive ephedrine
- 28 received ephedrine

25 included in analysis
Discontinued intervention (n=3)

Figure 2

Randomization and follow-up of the patients.
Figure 3

The change of mean arterial pressure (MAP), hearth rate (HR), cardiac index (CI), and stroke volume index (SVI) from the baseline until 30 min after SA in three groups of patients (Group C = control group; Group P = phenylephrine group; Group E = ephedrine group).